Peripheral T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Peripheral T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of duvelisib and venetoclax in relapsed or refractory peripheral T-cell lymphoma, w…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) [Phase 2]
A Phase 2 trial of Brentuximab vedotin in combination with CHP for CD30-positive Peripheral T-Cell Lymphoma in Chinese participants is curre…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System [Phase 1]
Phase 1 trial investigating safety and activity of a novel TNFR2 inhibitor in adults with non-Hodgkin lymphoma, including cutaneous T-cell l…
-
CLINICAL_TRIALS trial_result · 2025-07-04Clinical Trial Update: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) [Phase 2]
A Phase 2 clinical trial (JACKPOT26) evaluating AZD4205 in Peripheral T-cell Lymphoma after first-line therapy has completed.
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) [Phase 2]
A Phase 2 clinical trial evaluating the oral JAK1 inhibitor golidocitinib in newly diagnosed Peripheral T-cell lymphoma is not yet recruitin…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-15Clinical Trial Update: CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CD5-targeted CAR T-cell therapy for relapsed/refractory T-cell lymphomas is currently recruiting in Be…
-
CLINICAL_TRIALS trial_result · 2025-06-12Clinical Trial Update: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies [Phase 1]
Phase 1 trial evaluating a combination of romidepsin, CC-486 (oral azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refract…
-
CLINICAL_TRIALS trial_result · 2025-06-06Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safet…
-
CLINICAL_TRIALS research · 2025-06-04Clinical Trial Update: Expanded Access to Tipifarnib
Kura Oncology announced expanded access to Tipifarnib for patients with HRAS mutations or Peripheral T-Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
A completed observational study in Japanese patients with Peripheral T-cell Lymphoma who received second-line therapy.
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL [Phase 3]
This Phase 3 clinical trial compares mitoxantrone hydrochloride liposome injection to chidamide in patients with relapsed/refractory periphe…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression [Phase 2]
This is a Phase 2 frontline study report of brentuximab vedotin combined with CHP for peripheral T-cell lymphoma with low CD30 expression; r…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: GVM±R in Patients With Relapsed or Refractory Aggressive NHL. [Phase 2]
Phase 2 clinical trial update for GVM±R in adults with relapsed or refractory aggressive non-Hodgkin lymphoma, including Peripheral T-cell l…
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating CD7-directed CAR T-cell therapy for relapsed/refractory T-cell lymphomas (including PTCL and CTC…
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
A real-world study evaluating regimens based on golidocitinib for peripheral T-cell lymphoma is not yet recruiting, sponsored by Ruijin Hosp…
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
This is an international prospective registry enrolling patients with newly diagnosed Peripheral T-Cell Lymphoma to collect observational da…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating decitabine with gemcitabine and oxaliplatin for relapsed/refractory peripheral T-cell lymphoma has been terminate…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies [Phase 1]
A Phase 1 clinical study evaluating the CD70-targeted agent CHT101 in relapsed or refractory hematologic malignancies is currently recruitin…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) [Phase 1, Phase 2]
Results from the Phase 1/2 JACKPOT8 trial of the oral JAK inhibitor AZD4205 as monotherapy in relapsed or refractory peripheral T-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors [Phase 1]
Phase 1 trial of KT-333 in adults with refractory lymphomas and solid tumors reports safety, pharmacokinetics, pharmacodynamics, and prelimi…
-
CLINICAL_TRIALS research · 2025-03-11Clinical Trial Update: Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) [Phase 2]
A phase 2 clinical trial evaluating chidamide for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.
-
FDA approval · 2025-03-10FDA Approved: PRALATREXATE — Original Application (Dr.Reddy's Laboratories Inc.,)
FDA approved an Original Application for pralatrexate by Dr. Reddy's Laboratories Inc., enabling a generic version of the anti-cancer drug.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL [Phase 1, Phase 2]
This document reports a Phase I/II clinical trial evaluating golidocitinib in combination with pomalidomide for relapsed/refractory peripher…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
This update reports the results of a Phase 2 study of duvelisib in participants with relapsed or refractory peripheral T-cell lymphoma. The …